vs
Side-by-side financial comparison of ANI PHARMACEUTICALS INC (ANIP) and STURM RUGER & CO INC (RGR). Click either name above to swap in a different company.
ANI PHARMACEUTICALS INC is the larger business by last-quarter revenue ($247.1M vs $151.1M, roughly 1.6× STURM RUGER & CO INC). On growth, ANI PHARMACEUTICALS INC posted the faster year-over-year revenue change (29.6% vs 3.6%). ANI PHARMACEUTICALS INC produced more free cash flow last quarter ($29.1M vs $12.3M). Over the past eight quarters, ANI PHARMACEUTICALS INC's revenue compounded faster (34.1% CAGR vs 5.1%).
ANI Pharmaceuticals Inc is a U.S.-based specialty pharmaceutical firm that develops, manufactures and sells generic and branded prescription drugs. Its key segments cover dermatology, oncology, CNS therapies and anti-infectives, primarily serving U.S. healthcare providers, retail pharmacies and institutional medical clients.
Sturm, Ruger & Company, Inc., better known by the shortened name Ruger, is an American firearm manufacturing company based in Southport, Connecticut, with production facilities also in Newport, New Hampshire; Mayodan, North Carolina; and Prescott, Arizona. The company was founded in 1949 by Alexander McCormick Sturm and William B. Ruger and has been publicly traded since 1969.
ANIP vs RGR — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $247.1M | $151.1M |
| Net Profit | $27.5M | — |
| Gross Margin | — | 17.8% |
| Operating Margin | 14.1% | 2.3% |
| Net Margin | 11.1% | — |
| Revenue YoY | 29.6% | 3.6% |
| Net Profit YoY | 367.5% | — |
| EPS (diluted) | $1.14 | $0.22 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $247.1M | $151.1M | ||
| Q3 25 | $227.8M | $126.8M | ||
| Q2 25 | $211.4M | $132.5M | ||
| Q1 25 | $197.1M | $135.7M | ||
| Q4 24 | $190.6M | $145.8M | ||
| Q3 24 | $148.3M | $122.3M | ||
| Q2 24 | $138.0M | $130.8M | ||
| Q1 24 | $137.4M | $136.8M |
| Q4 25 | $27.5M | — | ||
| Q3 25 | $26.6M | $1.6M | ||
| Q2 25 | $8.5M | $-17.2M | ||
| Q1 25 | $15.7M | $7.8M | ||
| Q4 24 | $-10.3M | — | ||
| Q3 24 | $-24.2M | $4.7M | ||
| Q2 24 | $-2.3M | $8.3M | ||
| Q1 24 | $18.2M | $7.1M |
| Q4 25 | — | 17.8% | ||
| Q3 25 | — | 15.1% | ||
| Q2 25 | — | 3.9% | ||
| Q1 25 | — | 22.0% | ||
| Q4 24 | — | 22.8% | ||
| Q3 24 | — | 18.5% | ||
| Q2 24 | — | 22.3% | ||
| Q1 24 | — | 21.5% |
| Q4 25 | 14.1% | 2.3% | ||
| Q3 25 | 15.9% | -2.7% | ||
| Q2 25 | 6.6% | -15.6% | ||
| Q1 25 | 13.3% | 6.2% | ||
| Q4 24 | -2.3% | 7.8% | ||
| Q3 24 | -13.8% | 3.1% | ||
| Q2 24 | 3.7% | 6.9% | ||
| Q1 24 | 14.8% | 5.5% |
| Q4 25 | 11.1% | — | ||
| Q3 25 | 11.7% | 1.2% | ||
| Q2 25 | 4.0% | -13.0% | ||
| Q1 25 | 8.0% | 5.7% | ||
| Q4 24 | -5.4% | — | ||
| Q3 24 | -16.3% | 3.9% | ||
| Q2 24 | -1.7% | 6.3% | ||
| Q1 24 | 13.2% | 5.2% |
| Q4 25 | $1.14 | $0.22 | ||
| Q3 25 | $1.13 | $0.10 | ||
| Q2 25 | $0.36 | $-1.05 | ||
| Q1 25 | $0.69 | $0.46 | ||
| Q4 24 | $-0.45 | $0.62 | ||
| Q3 24 | $-1.27 | $0.28 | ||
| Q2 24 | $-0.14 | $0.47 | ||
| Q1 24 | $0.82 | $0.40 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $285.6M | $92.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $540.7M | $283.8M |
| Total Assets | $1.4B | $342.0M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $285.6M | $92.5M | ||
| Q3 25 | $262.6M | $80.8M | ||
| Q2 25 | $217.8M | $101.4M | ||
| Q1 25 | $149.8M | $108.3M | ||
| Q4 24 | $144.9M | $105.5M | ||
| Q3 24 | $145.0M | $96.0M | ||
| Q2 24 | $240.1M | $105.6M | ||
| Q1 24 | $228.6M | $115.3M |
| Q4 25 | $540.7M | $283.8M | ||
| Q3 25 | $505.8M | $279.6M | ||
| Q2 25 | $436.8M | $289.3M | ||
| Q1 25 | $418.6M | $321.5M | ||
| Q4 24 | $403.7M | $319.6M | ||
| Q3 24 | $405.9M | $314.9M | ||
| Q2 24 | $455.8M | $321.5M | ||
| Q1 24 | $452.0M | $332.0M |
| Q4 25 | $1.4B | $342.0M | ||
| Q3 25 | $1.4B | $342.3M | ||
| Q2 25 | $1.3B | $349.5M | ||
| Q1 25 | $1.3B | $379.0M | ||
| Q4 24 | $1.3B | $384.0M | ||
| Q3 24 | $1.3B | $373.5M | ||
| Q2 24 | $920.8M | $376.7M | ||
| Q1 24 | $914.5M | $385.0M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $30.4M | $15.5M |
| Free Cash FlowOCF − Capex | $29.1M | $12.3M |
| FCF MarginFCF / Revenue | 11.8% | 8.2% |
| Capex IntensityCapex / Revenue | 0.5% | 2.1% |
| Cash ConversionOCF / Net Profit | 1.10× | — |
| TTM Free Cash FlowTrailing 4 quarters | $171.4M | $38.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $30.4M | $15.5M | ||
| Q3 25 | $44.1M | $12.9M | ||
| Q2 25 | $75.8M | $14.7M | ||
| Q1 25 | $35.0M | $11.1M | ||
| Q4 24 | $15.9M | $20.0M | ||
| Q3 24 | $12.5M | $9.4M | ||
| Q2 24 | $17.4M | $18.7M | ||
| Q1 24 | $18.3M | $7.3M |
| Q4 25 | $29.1M | $12.3M | ||
| Q3 25 | $38.0M | $7.0M | ||
| Q2 25 | $71.8M | $9.1M | ||
| Q1 25 | $32.5M | $10.0M | ||
| Q4 24 | $13.5M | $16.4M | ||
| Q3 24 | $7.7M | $2.6M | ||
| Q2 24 | $13.0M | $10.1M | ||
| Q1 24 | $13.7M | $5.6M |
| Q4 25 | 11.8% | 8.2% | ||
| Q3 25 | 16.7% | 5.5% | ||
| Q2 25 | 34.0% | 6.9% | ||
| Q1 25 | 16.5% | 7.4% | ||
| Q4 24 | 7.1% | 11.2% | ||
| Q3 24 | 5.2% | 2.1% | ||
| Q2 24 | 9.4% | 7.7% | ||
| Q1 24 | 10.0% | 4.1% |
| Q4 25 | 0.5% | 2.1% | ||
| Q3 25 | 2.7% | 4.6% | ||
| Q2 25 | 1.9% | 4.2% | ||
| Q1 25 | 1.3% | 0.8% | ||
| Q4 24 | 1.3% | 2.5% | ||
| Q3 24 | 3.2% | 5.5% | ||
| Q2 24 | 3.2% | 6.6% | ||
| Q1 24 | 3.3% | 1.3% |
| Q4 25 | 1.10× | — | ||
| Q3 25 | 1.66× | 8.15× | ||
| Q2 25 | 8.87× | — | ||
| Q1 25 | 2.23× | 1.43× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 1.98× | ||
| Q2 24 | — | 2.27× | ||
| Q1 24 | 1.00× | 1.04× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
RGR
| Firearms | $150.6M | 100% |
| Castings | $7.3M | 5% |
